CI · Insider Trading
The Cigna Group
Every open-market purchase and sale reported by CI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-08 | Everett Neville | See Remarks | Sell | −617 | −$175.26K |
| 2026-09-03 | Brian C Evanko | See Remarks | A | +3,113 | — |
| 2026-09-02 | George Kurian | Director | A | +108 deriv. | — |
| 2026-08-20 | Nicole S Jones | See Remarks | Sell | −2,677 | −$748.52K |
| 2026-08-20 | Bryan Holgerson | See Remarks | A | — | — |
| 2026-08-06 | Nicole S Jones | See Remarks | MIXED | −4,090 | −$2.42M |
| 2026-08-06 | Nicole S Jones | See Remarks | MIXED | −4,090 | −$2.42M |
| 2026-06-16 | Jamie G Kates | Chief Accounting Officer | MIXED | — | −$131.00K |
| 2026-06-03 | Durga Prasad Koka | EVP, Global CIO | F | −729 | −$200.86K |
| 2026-06-02 | George Kurian | Director | A | +108 deriv. | — |
| 2026-05-14 | David Cordani | Chairman & CEO | MIXED | +10,665 | −$22.91M |
| 2026-04-24 | Eric C Wiseman | Director | A | +782 | — |
| 2026-04-24 | Philip Ozuah | Director | A | +782 | — |
| 2026-04-24 | Michael J Hennigan | Director | A | +782 | — |
| 2026-04-24 | Kimberly A. Ross | Director | A | +782 | — |
| 2026-04-24 | George Kurian | Director | A | +782 | — |
| 2026-04-24 | Kathleen M Mazzarella | Director | A | +782 | — |
| 2026-04-24 | Donna F Zarcone | Director | A | +782 | — |
| 2026-04-24 | Neesha Hathi | Director | A | +782 | — |
| 2026-04-24 | Mark B. McClellan | Director | A | +782 | — |
| 2026-04-24 | Eric J Foss | Director | A | +782 | — |
| 2026-03-03 | George Kurian | Director | A | +103 deriv. | — |
| 2026-03-03 | David Cordani | Chairman & CEO | MIXED | +25,745 | −$4.44M |
| 2026-03-03 | Ann M Dennison | EVP, CFO | MIXED | +4,825 | −$117.61K |
| 2026-03-03 | Brian C Evanko | See Remarks | MIXED | +11,448 | −$1.37M |
| 2026-03-03 | Nicole S Jones | See Remarks | MIXED | +4,322 | −$1.45M |
| 2026-03-03 | Everett Neville | See Remarks | MIXED | +2,161 | −$899.21K |
| 2026-03-03 | Durga Prasad Koka | EVP, Global CIO | MIXED | +2,957 | −$63.26K |
| 2026-03-03 | Jamie G Kates | Chief Accounting Officer | MIXED | +682 | −$37.96K |
| 2025-12-02 | George Kurian | Director | A | +108 deriv. | — |
| 2025-11-03 | David Cordani | Chairman & CEO | Buy | +4,134 | +$999.92K |
| 2025-10-07 | Brian C Evanko | See Remarks | MIXED | +901 | −$737.63K |
| 2025-09-03 | David J Brailer | EVP & Chief Health Officer | F | −290 | −$87.19K |
| 2025-09-03 | George Kurian | Director | A | +99 deriv. | — |
| 2025-08-19 | Nicole S Jones | See Remarks | MIXED | −1,096 | −$3.32M |
| 2025-06-04 | Michael J Hennigan | Director | A | +568 | — |
| 2025-06-03 | George Kurian | Director | A | +94 deriv. | — |
| 2025-04-25 | Eric J Foss | Director | A | +638 | — |
| 2025-04-25 | Elder Granger | Director | A | +638 | — |
| 2025-04-25 | Neesha Hathi | Director | A | +638 | — |
| 2025-04-25 | Kathleen M Mazzarella | Director | A | +638 | — |
| 2025-04-25 | Mark B. McClellan | Director | A | +638 | — |
| 2025-04-25 | Philip Ozuah | Director | A | +638 | — |
| 2025-04-25 | Kimberly A. Ross | Director | A | +638 | — |
| 2025-04-25 | George Kurian | Director | A | +638 | — |
| 2025-04-25 | Eric C Wiseman | Director | A | +638 | — |
| 2025-04-25 | Donna F Zarcone | Director | A | +638 | — |
| 2025-03-17 | Elder Granger | Director | MIXED | — | −$377.48K |
| 2025-03-11 | Noelle K Eder | See Remarks | Sell | −9,944 | −$3.18M |
| 2025-03-04 | Nicole S Jones | See Remarks | MIXED | +2,198 | −$3.07M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| David Cordani | Chairman & CEO | 307,285 | $94.32M |
| Eric P Palmer | See Remarks | 70,504 | $21.64M |
| Brian C Evanko | See Remarks | 66,644 | $20.46M |
| Eric J Foss | Director | 36,696 | $11.26M |
| Donna F Zarcone | Director | 27,517 | $8.45M |
| Nicole S Jones | See Remarks | 27,331 | $8.39M |
| Eric C Wiseman | Director | 23,940 | $7.35M |
| David J Brailer | EVP & Chief Health Officer | 17,525 | $5.38M |
| Noelle K Eder | See Remarks | 13,590 | $4.17M |
| Ann M Dennison | EVP, CFO | 7,745 | $2.38M |
| Kathleen M Mazzarella | Director | 6,891 | $2.12M |
| Mark B. McClellan | Director | 6,891 | $2.12M |
| Durga Prasad Koka | EVP, Global CIO | 6,552 | $2.01M |
| Elder Granger | Director | 6,109 | $1.88M |
| Kimberly A. Ross | Director | 5,294 | $1.62M |
| Everett Neville | See Remarks | 5,053 | $1.55M |
| George Kurian | Director | 4,560 | $1.40M |
| Neesha Hathi | Director | 4,151 | $1.27M |
| Jamie G Kates | Chief Accounting Officer | 3,267 | $1.00M |
| Philip Ozuah | Director | 2,583 | $792.85K |
| Michael J Hennigan | Director | 1,350 | $414.38K |
| Bryan Holgerson | See Remarks | 735 | $225.89K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.